Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma

被引：31

作者：

Ali, Shaukat ^{[1
,2
]}

Uddin, Syed M. ^{[1
]}

Ali, Ayesha ^{[1
]}

Anjum, Fatima ^{[2
]}

Ali, Rashid ^{[1
]}

Shalim, Elisha ^{[1
]}

Khan, Mujtaba ^{[1
]}

Ahmed, Iqra ^{[1
]}

M Muhaymin, Sheikh ^{[1
]}

Bukhari, Uzma ^{[3
]}

Luxmi, Shobha ^{[4
]}

Khan, Abdul S. ^{[5
]}

Quraishy, Saeed ^{[6
]}

机构：

[1] Dow Univ Hlth Sci, Dow Coll Biotechnol, Karachi, Pakistan

[2] Dow Univ Hlth Sci, Dow Res Inst Biotechnol & Biomed Sci, Karachi, Pakistan

[3] Dow Univ Hlth Sci, Dow Int Med Coll, Karachi, Pakistan

[4] Dow Univ Hlth Sci, Dow Univ Hosp, Karachi, Pakistan

[5] Natl Control Lab Biol, Islamabad, Pakistan

[6] Dow Univ Hlth Sci, Karachi, Pakistan

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 05期

关键词：

convalescent plasma; SARS-CoV-2; intravenous immunoglobulins; anti-COVID-19; IVIG; passive immunization; pooled plasma; caprylic acid; ultrafiltration; diafiltration; immunotherapy; PREVENTION; THERAPY;

D O I：

10.2217/imt-2020-0263

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 +/- 30 cut-off index) that of the PCP (36 +/- 8.5 cut-off index) and mean protein concentration was found to be 46 +/- 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT 04521309).

引用

页码：397 / 407

页数：11

共 38 条

[11] Effectiveness of convalescent plasma therapy in severe COVID-19 patients [J].

Duan, Kai ;

Liu, Bende ;

Li, Cesheng ;

Zhang, Huajun ;

Yu, Ting ;

Qu, Jieming ;

Zhou, Min ;

Chen, Li ;

Meng, Shengli ;

Hu, Yong ;

Peng, Cheng ;

Yuan, Mingchao ;

Huang, Jinyan ;

Wang, Zejun ;

Yu, Jianhong ;

Gao, Xiaoxiao ;

Wang, Dan ;

Yu, Xiaoqi ;

Li, Li ;

Zhang, Jiayou ;

Wu, Xiao ;

Li, Bei ;

Xu, Yanping ;

Chen, Wei ;

Peng, Yan ;

Hu, Yeqin ;

Lin, Lianzhen ;

Liu, Xuefei ;

Huang, Shihe ;

Zhou, Zhijun ;

Zhang, Lianghao ;

Wang, Yue ;

Zhang, Zhi ;

Deng, Kun ;

Xia, Zhiwu ;

Gong, Qin ;

Zhang, Wei ;

Zheng, Xiaobei ;

Liu, Ying ;

Yang, Huichuan ;

Zhou, Dongbo ;

Yu, Ding ;

Hou, Jifeng ;

Shi, Zhengli ;

Chen, Saijuan ;

Chen, Zhu ;

Zhang, Xinxin ;

Yang, Xiaoming .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (17) :9490-9496

[12] Minipool Caprylic Acid Fractionation of Plasma Using Disposable Equipment: A Practical Method to Enhance Immunoglobulin Supply in Developing Countries [J].

El-Ekiaby, Magdy ;

Vargas, Mariangela ;

Sayed, Makram ;

Gorgy, George ;

Goubran, Hadi ;

Radosevic, Mirjana ;

Burnouf, Thierry .

PLOS NEGLECTED TROPICAL DISEASES, 2015, 9 (02)

[13]

Fernandes Nuno, 2020, SSRN Electron. J., DOI [DOI 10.2139/SSRN.3557504, 10.2139/ssrn.3557504]

[14] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

[15] Passive immunity in prevention and treatment of infectious diseases [J].

Keller, MA ;

Stiehm, ER .

CLINICAL MICROBIOLOGY REVIEWS, 2000, 13 (04) :602-+

[16] Looking beyond COVID-19 vaccine phase 3 trials [J].

Kim, Jerome H. ;

Marks, Florian ;

Clemens, John D. .

NATURE MEDICINE, 2021, 27 (02) :205-211

[17]

Kloft, 1992, Patent No. 5164487

[18] CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].

LAEMMLI, UK .

NATURE, 1970, 227 (5259) :680-+

[19]

Lane D., 1988, ANTIBODIES LAB MANUA, P579

[20]

Morais V, 2014, METHODS MOL BIOL, V1129, P137, DOI [10.1007/978-1-52703-977-2_13, 10.1007/978-1-62703-977-2_13]

← 1 2 3 4 →